Gd-EOB-DTPA增强MRI T_1 mapping技术在肝脏疾病的应用进展
|
摘要
T_1 mapping成像是定量分析组织T_1值的方法,主要包括Look-Locker(LL)序列、改良的Look-Locker反转恢复序列(MOLLI)及可变多翻转角成像技术。近年来,基于Gd-EOB-DTPA的T_1 mapping成像广泛应用于肝脏。根据注射对比剂前后肝实质的T_1变化,不仅能用于对肝脏损伤程度、肝纤维化分期、肝硬化病人肝储备功能的评估,而且对肝脏局灶性病变的鉴别、肝细胞肝癌分化程度的预测也有一定的价值。就Gd-EOB-DTPA增强MRI T_1 mapping技术在肝脏疾病中的应用现状及研究进展予以综述。
T_1 mapping technique is a method to quantitatively analyze T_1 of tissue. It includes Look-Locker, modified Look-Locker IR(MOLLI) and variable flip angle sequences, et al. In recent years, T_1 mapping based on Gd-EOB-DTPA enhancement was widely used in liver exams. According to the changes of T_1 before and after the contrast injection, T_1 mapping can not only evaluate the degree of liver injury, stage liver fibrosis, and estimate liver reserve function, but also distinguish liver focal lesions and predict the degree of differentiation of hepatocellular carcinoma. We reviewed the current application of Gd-EOB-DTPA-enhanced MRI T_1 mapping and its research progresses in liver diseases.
T_1 mapping technique is a method to quantitatively analyze T_1 of tissue. It includes Look-Locker, modified Look-Locker IR(MOLLI) and variable flip angle sequences, et al. In recent years, T_1 mapping based on Gd-EOB-DTPA enhancement was widely used in liver exams. According to the changes of T_1 before and after the contrast injection, T_1 mapping can not only evaluate the degree of liver injury, stage liver fibrosis, and estimate liver reserve function, but also distinguish liver focal lesions and predict the degree of differentiation of hepatocellular carcinoma. We reviewed the current application of Gd-EOB-DTPA-enhanced MRI T_1 mapping and its research progresses in liver diseases.
引文
[1]Pascolo L,Cupelli F,Anelli PL,et al.Molecular mechanisms for the hepatic uptake of magnetic re sonance imaging contrast agents[J].Biochem Biophys Res Commun,1999,257:746-752.
[2]Tamada T,Ito K,Higaki A,et al.Gd-EOB-DTPA-enhanced MRimaging:evaluation of hepatic enhancement effects in normal and cirrhotic livers[J].Eur J Radiol,2011,80:e311-e316.
[3]Tajima T,Takao H,Akai H,et al.Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging[J].J Comput Assist Tomogr,2010,34:362-366.
[4]Yoshimura N,Saito K,Saguchi T,et al.Distinguishing hepatic hemangiomas from metastatic tumors using T1mapping on gadoxeticacid-enhanced MRI[J].Magn Reson Imaging,2013,31:23-27.
[5]Shah NJ,Neeb H,Zaitsev M,et al.Quantitative T1mapping of hepatic encephalopathy using magnetic resonance imaging[J].Hepatology,2003,38:1219-1226.
[6]Everett RJ,Stirrat CG,Semple SI,et al.Assessment of myocardial fibrosis with T1mapping MRI[J].Clin Radiol,2016,71:768-778.
[7]Messroghli DR,Radjenovic A,Kozerke S,et al.Modified LookLocker inversion recovery(MOLLI)for high-resolution T1mapping of the heart[J].Magn Reson Med,2004,52:141-146.
[8]Zhou ZP,Long LL,Qiu WJ,et al.Evaluating segmental liver function using T1mapping on Gd-EOB-DTPA-enhanced MRI with a 3.0Tesla[J].BMC Med Imaging,2017,17:20.
[9]Haimerl M,Utpatel K,Verloh N,et al.Gd-EOB-DTPA-enhanced MR relaxometry for the detection and staging of liver fibrosis[J].Sci Rep,2017,7:41429.
[10]Haimerl M,Verloh N,Zeman F,et al.Gd-EOB-DTPA-enhanced MRI for evaluation of liver function:Comparison between signal-intensity-based indices and T1relaxometry[J].Sci Rep,2017,7:43347.
[11]Yoon JH,Lee JM,Kim E,et al.Quantitative liver function analysis:volumetric T1mapping with fast multisection B1 inhomogeneity correction in hepatocyte-specific contrast-enhanced liver MR imaging[J].Radiology,2017,282:408-417.
[12]Speliotes EK,Butler JL,Palmer CD,et al.PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease[J].Hepatology,2010,52:904-912.
[13]Dowman JK,Tomlinson JW,Newsome PN.Systematic review:the diagnosis and staging of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis[J].Aliment Pharmacol Ther,2011,33:525-540.
[14]Ding Y,Rao SX,Meng T,et al.Usefulness of T1 mapping on GdEOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease[J].Eur Radiol,2014,24:959-966.
[15]Ding Y,Rao SX,Chen C,et al.Potential of Gd-EOB-DTPA-enhanced MR imaging for evaluation of bile duct ligation-induced liver injury in rabbits[J].Hepatol Int,2015,9:303-309.
[16]Hinrichs H,Hinrichs JB,Gutberlet M,et al.Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis(PSC)[J].Eur Radiol,2016,26:1116-1124.
[17]Ding Y,Rao SX,Yang L,et al.Comparison of the effect of regionof-interest methods using gadoxetic acid-enhanced MR imaging with diffusion-weighted imaging on staging hepatic fibrosis[J].Radiol Med,2016,121:821-827.
[18]Yang L,Ding Y,Rao S,et al.Staging liver fibrosis in chronic hepatitis B with T1relaxation time index on gadoxetic acid-enhanced MRI:comparison with aspartate aminotransferase-to-platelet ratio index and FIB-4[J].J Magn Reson Imaging,2017,45:1186-1194.
[19]Sheng RF,Wang HQ,Yang L,et al.Assessment of liver fibrosis using T1mapping on Gd-EOB-DTPA-enhanced magnetic resonance[J].Dig Liver Dis,2017,49:789-795.
[20]Pan S,Wang XQ,Guo QY.Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C:T1mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging[J].World J Gastroenterol,2018,24:2024-2035.
[21]Yoneyama T,Fukukura Y,Kamimura K,et al.Efficacy of liver parenchymal enhancement and liver volume to standard liver volume ratio on Gd-EOB-DTPA-enhanced MRI for estimation of liver function[J].Eur Radiol,2014,24:857-865.
[22]Ding Y,Rao SX,Chen C,et al.Assessing liver function in patients with HBV-related HCC:a comparison of T1mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI[J].Eur Radiol,2015,25:1392-1398.
[23]Zhou ZP,Long LL,Qiu WJ,et al.Comparison of 10-and 20-min hepatobiliary phase images on Gd-EOB-DTPA-enhanced MRI T1mapping for liver function assessment in clinic[J].Abdom Radiol(NY),2017,42:2272-2278.
[24]Peng ZP,Li ZP,Li C,et al.Quantitative evaluation of Gd-EOB-DTPA uptake in focal live lesions by using T1mapping:differences between hepatocellular carcinoma,hepatic focal nodular hyperplasia and cavernous hemangioma[J].Oncotarget,2017,8:65435-6544.
[25]Yoshimura N,Saito K,Saguchi T,et al.Distinguishing hepatic hemangiomas from metastatic tumors using T1mapping on gadoxeticacid-enhanced MRI[J].Magn Reson Imaging,2013,31:23-27.
[26]Peng ZP,Jiang MJ,Cai HS,et al.Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with T1 mapping predicts the degree of differentiation in hepatocellular carcinoma[J].BMC Cancer,2016,16:625.
[27]Chen CY,Chen J,Xia CC,et al.T1mapping combined with GdEOB-DTPA-enhanced magnetic resonance imaging in predicting the pathologic grading of hepatocellular carcinoma[J].J Biol Regul Homeost Agents,2017,31:1029-1036.
[28]Katsube T,Okada M,Kumano S,et al.Estimation of liver function using T1mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging[J].Invest Radial,2011,46:277-283.
[29]Haimerl M,Verloh N,Fellner C,et al.MRI-based estimation of liver function:Gd-EOB-DTPA-enhanced T1relaxometry of 3 T vs.the MELD score[J].Sci Rep,2014,4:5621.(收稿2018-06-05)
[2]Tamada T,Ito K,Higaki A,et al.Gd-EOB-DTPA-enhanced MRimaging:evaluation of hepatic enhancement effects in normal and cirrhotic livers[J].Eur J Radiol,2011,80:e311-e316.
[3]Tajima T,Takao H,Akai H,et al.Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging[J].J Comput Assist Tomogr,2010,34:362-366.
[4]Yoshimura N,Saito K,Saguchi T,et al.Distinguishing hepatic hemangiomas from metastatic tumors using T1mapping on gadoxeticacid-enhanced MRI[J].Magn Reson Imaging,2013,31:23-27.
[5]Shah NJ,Neeb H,Zaitsev M,et al.Quantitative T1mapping of hepatic encephalopathy using magnetic resonance imaging[J].Hepatology,2003,38:1219-1226.
[6]Everett RJ,Stirrat CG,Semple SI,et al.Assessment of myocardial fibrosis with T1mapping MRI[J].Clin Radiol,2016,71:768-778.
[7]Messroghli DR,Radjenovic A,Kozerke S,et al.Modified LookLocker inversion recovery(MOLLI)for high-resolution T1mapping of the heart[J].Magn Reson Med,2004,52:141-146.
[8]Zhou ZP,Long LL,Qiu WJ,et al.Evaluating segmental liver function using T1mapping on Gd-EOB-DTPA-enhanced MRI with a 3.0Tesla[J].BMC Med Imaging,2017,17:20.
[9]Haimerl M,Utpatel K,Verloh N,et al.Gd-EOB-DTPA-enhanced MR relaxometry for the detection and staging of liver fibrosis[J].Sci Rep,2017,7:41429.
[10]Haimerl M,Verloh N,Zeman F,et al.Gd-EOB-DTPA-enhanced MRI for evaluation of liver function:Comparison between signal-intensity-based indices and T1relaxometry[J].Sci Rep,2017,7:43347.
[11]Yoon JH,Lee JM,Kim E,et al.Quantitative liver function analysis:volumetric T1mapping with fast multisection B1 inhomogeneity correction in hepatocyte-specific contrast-enhanced liver MR imaging[J].Radiology,2017,282:408-417.
[12]Speliotes EK,Butler JL,Palmer CD,et al.PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease[J].Hepatology,2010,52:904-912.
[13]Dowman JK,Tomlinson JW,Newsome PN.Systematic review:the diagnosis and staging of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis[J].Aliment Pharmacol Ther,2011,33:525-540.
[14]Ding Y,Rao SX,Meng T,et al.Usefulness of T1 mapping on GdEOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease[J].Eur Radiol,2014,24:959-966.
[15]Ding Y,Rao SX,Chen C,et al.Potential of Gd-EOB-DTPA-enhanced MR imaging for evaluation of bile duct ligation-induced liver injury in rabbits[J].Hepatol Int,2015,9:303-309.
[16]Hinrichs H,Hinrichs JB,Gutberlet M,et al.Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis(PSC)[J].Eur Radiol,2016,26:1116-1124.
[17]Ding Y,Rao SX,Yang L,et al.Comparison of the effect of regionof-interest methods using gadoxetic acid-enhanced MR imaging with diffusion-weighted imaging on staging hepatic fibrosis[J].Radiol Med,2016,121:821-827.
[18]Yang L,Ding Y,Rao S,et al.Staging liver fibrosis in chronic hepatitis B with T1relaxation time index on gadoxetic acid-enhanced MRI:comparison with aspartate aminotransferase-to-platelet ratio index and FIB-4[J].J Magn Reson Imaging,2017,45:1186-1194.
[19]Sheng RF,Wang HQ,Yang L,et al.Assessment of liver fibrosis using T1mapping on Gd-EOB-DTPA-enhanced magnetic resonance[J].Dig Liver Dis,2017,49:789-795.
[20]Pan S,Wang XQ,Guo QY.Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C:T1mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging[J].World J Gastroenterol,2018,24:2024-2035.
[21]Yoneyama T,Fukukura Y,Kamimura K,et al.Efficacy of liver parenchymal enhancement and liver volume to standard liver volume ratio on Gd-EOB-DTPA-enhanced MRI for estimation of liver function[J].Eur Radiol,2014,24:857-865.
[22]Ding Y,Rao SX,Chen C,et al.Assessing liver function in patients with HBV-related HCC:a comparison of T1mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI[J].Eur Radiol,2015,25:1392-1398.
[23]Zhou ZP,Long LL,Qiu WJ,et al.Comparison of 10-and 20-min hepatobiliary phase images on Gd-EOB-DTPA-enhanced MRI T1mapping for liver function assessment in clinic[J].Abdom Radiol(NY),2017,42:2272-2278.
[24]Peng ZP,Li ZP,Li C,et al.Quantitative evaluation of Gd-EOB-DTPA uptake in focal live lesions by using T1mapping:differences between hepatocellular carcinoma,hepatic focal nodular hyperplasia and cavernous hemangioma[J].Oncotarget,2017,8:65435-6544.
[25]Yoshimura N,Saito K,Saguchi T,et al.Distinguishing hepatic hemangiomas from metastatic tumors using T1mapping on gadoxeticacid-enhanced MRI[J].Magn Reson Imaging,2013,31:23-27.
[26]Peng ZP,Jiang MJ,Cai HS,et al.Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with T1 mapping predicts the degree of differentiation in hepatocellular carcinoma[J].BMC Cancer,2016,16:625.
[27]Chen CY,Chen J,Xia CC,et al.T1mapping combined with GdEOB-DTPA-enhanced magnetic resonance imaging in predicting the pathologic grading of hepatocellular carcinoma[J].J Biol Regul Homeost Agents,2017,31:1029-1036.
[28]Katsube T,Okada M,Kumano S,et al.Estimation of liver function using T1mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging[J].Invest Radial,2011,46:277-283.
[29]Haimerl M,Verloh N,Fellner C,et al.MRI-based estimation of liver function:Gd-EOB-DTPA-enhanced T1relaxometry of 3 T vs.the MELD score[J].Sci Rep,2014,4:5621.(收稿2018-06-05)